NCT05788237 - A Study to Examine Respiratory Combination Vaccines Against Respiratory Syncytial Virus (RSV) and Flu in Older Adults | Biotech Hunter

Enrollment

508

Participants

Timeline

Start Date

March 9, 2023

Primary Completion Date

September 27, 2023

Study Completion Date

September 27, 2023

Conditions

Healthy

Interventions

BIOLOGICAL

RSVpreF+qIRV

RSVpreF containing 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B combined with Quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 strains as recommended for the influenza season (2 A strains, 2 B strains)

BIOLOGICAL

qIRV

Quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 strains as recommended for the influenza season (2 A strains, 2 B strains)

BIOLOGICAL

RSVpreF

RSVpreF containing 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B

DRUG

Placebo

0.9% saline for injection

BIOLOGICAL

RSVpreF + qIRV 1.0 mL formulation

RSVpreF containing 2 Stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B plus qIRV Encoding HA of 4 strains as recommended for the influenza season (2 A strains and 2 B strains) plus sterile water as diluent for injection

BIOLOGICAL

RSVpreF + qIRV 0.5 mL formulation

Trial Locations (1)

1426

Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, Buenos Aires